Table 2. Base-Case Results Over Different Time Horizons.
| No. of months | Strategy | Costs, $ | QALYs | ICER ($/QALY) | NMB, $ | BMI | ||
|---|---|---|---|---|---|---|---|---|
| Cumulative | Incremental | Cumulative | Incremental | |||||
| 60 | No semaglutide or ESG | NA | NA | 3.55 | NA | NA | NA | 37.8 |
| 12 | ESG | 17 229 | 5488 | 0.72 | 0.002 | 240 265 | 54 996 | 32.2 |
| 12 | Semaglutide | 11 742 | 0.72 | 0 | 60 255 | 32.9 | ||
| 24 | ESG | 19 685 | 3162 | 1.47 | −0.009 | 0 | 127 288 | 32.2 |
| 24 | Semaglutide | 22 848 | 1.46 | −347 584 | 123 216 | 32.9 | ||
| 36 | ESG | 19 685 | 14 003 | 2.23 | −0.02 | 0 | 202 853 | 31.6 |
| 36 | Semaglutide | 33 688 | 2.20 | −599 580 | 186 515 | 32.9 | ||
| 48 | ESG | 19 685 | 24 129 | 2.95 | −0.04 | 0 | 275 691 | 31.7 |
| 48 | Semaglutide | 43 814 | 2.92 | −617 831 | 247 653 | 32.9 | ||
| 60 | ESG | 19 685 | 33 583 | 3.66 | −0.06 | 0 | 345 854 | 31.7 |
| 60 | Semaglutide | 53 268 | 3.60 | −595 532 | 306 632 | 33.0 | ||
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ESG, endoscopic sleeve gastroplasty; ICER, incremental cost-effectiveness ratio; NA, not applicable; NMB, net monetary benefit; QALY, quality-adjusted life-year.